Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

– Leverages Poseida’s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs targeting solid tumors – TOKYO and SAN DIEGO , May 1, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , “Astellas”) and Poseida Therapeutics ,